China SXT Pharmaceuticals, Inc. (SXTC)
After hours:
| Previous close | 0.9900 |
| Open | 0.9800 |
| Bid | 1.0300 x 200 |
| Ask | 1.0200 x 100 |
| Day's range | 0.9449 - 1.0800 |
| 52-week range | 0.9400 - 9.3750 |
| Volume | |
| Avg. volume | 1,236,733 |
| Market cap | 576,843 |
| Beta (5Y monthly) | 1.03 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -26.9600 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireChina SXT Pharmaceuticals, Inc. Regained Compliance with Nasdaq’s Minimum Bid Price Rule
TAIZHOU, China, Oct. 26, 2023 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ: SXTC), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS"), today announced that on October 19, 2023, NASDAQ notified us that it ha
- GlobeNewswire
China SXT Pharmaceuticals Announces One-for-Twenty-five Reverse Stock Split
Ordinary Shares Will Begin Trading on a Split-Adjusted Basis on October 5, 2023TAIZHOU, China, Oct. 04, 2023 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. ("SXTC" or the "Company"), (NASDAQ: SXTC), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("T
Simply Wall St.China SXT Pharmaceuticals Full Year 2023 Earnings: US$0.89 loss per share (vs US$5.52 loss in FY 2022)
China SXT Pharmaceuticals ( NASDAQ:SXTC ) Full Year 2023 Results Key Financial Results Net loss: US$5.93m (loss widened...
